Immune Responses After a Four-site Intradermal Rabies Booster Vaccination in HIV-infected Adults

Humoral and Cell-mediated Immune Responses After a Four-site Intradermal Rabies Booster Vaccination in Previously Rabies Immunized HIV-infected Adults

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02547727

Enrollment

Registered

2015-09-11

Start date

2016-02-29

Completion date

2023-12-31

Last updated

2022-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rabies

Keywords

rabies vaccination

Brief summary

A four-site intradermal rabies booster vaccination in HIV - infected patients who have ever received primary rabies vaccination could improve their immune response to this kind of vaccine.

Detailed description

A four-site intradermal rabies booster vaccination has shown higher immune response than conventional intramuscular rabies booster vaccination in healthy persons. So, the investigators hypothesized the same outcome in HIV - infected patients.

Interventions

BIOLOGICALrabies vaccine

Rabies vaccine is injected according to the protocol then blood would be drawn for rabies neutralizing antibody, OX-40 assay and cytokines assessment on day 0,7,14.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Inclusion criteria

* HIV infected patients * Age 18 - 60 years * Received primary rabies immunization

Exclusion criteria

* Have any active opportunistic infections * Received blood or blood product within 3 months * Allergy to vaccine or any vaccine components * Received anti-malarial drugs

Design outcomes

Primary

Measure	Time frame	Description
Rabies neutralizing antibody titers	Change from baseline of geometric mean titres of rabies neutralizing antibody titres at 2 weeks	Rabies neutralizing antibody titers would be represented and compared by geometric mean titers (GMTs)

Secondary

Measure	Time frame	Description
Specific T cell response	Change from baseline of percentages of rabies-antigen specific CD4+ T cells at 2 weeks	Specific T cell response is measured by OX-40 assay
Cytokines assessment	Change from baseline of cytokines levels at 1 week	A few cytokines levels are measured by multiplex bead array assay

Countries

Thailand

Contacts

Primary ContactSuda Sibunruang, MD

sudapunrin@gmail.com+66 81 7366076

Backup ContactTerapong Tantawichien, MD

terapong_tantawichien@hotmail.com+66 81 7350654

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026